{
  "hash": "13e46e52bbdc739a7bd54bc5cbdfd273",
  "result": {
    "markdown": "---\ntitle: \"\"\nexecute:   \n  freeze: auto  # re-render only when source changes\noutput: \n  rmarkdown::html_document:\n    highlight: pygments\n    number_sections: yes\n    self_contained: yes\n    toc: yes\n    toc_depth: 2\n    toc_float: yes\n---\n\n\n\n\n::: {.panel-tabset .nav-pills}\n\n\n\n\n::: {.cell}\n\n:::\n\n# Posts on linkedin {-} \n\n::: {.cell}\n::: {.cell-output-display}\n|                                                                                                                                                                                              |\n|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n|2024-06-30: **Non-proportional hazards in drug development** &#124; [link](https://www.linkedin.com/posts/kasparrufibach_biostatistics-survival-estimand-activity-7213277769428779008-IqOv?utm_source=share&utm_medium=member_desktop) &#124;|\n|2024-05-31: **SAVVY overview paper with recommendations on updates of safety guidelines** &#124; [link](https://www.linkedin.com/posts/kasparrufibach_biostatistics-safety-benefitrisk-activity-7202352154823573504-Upwe?utm_source=share&utm_medium=member_desktop) &#124;|\n|2024-03-06: **False negative risk of futility analyses is typically overestimated** &#124; [link](https://www.linkedin.com/posts/kasparrufibach_biostatistics-interimanalysis-trialdesign-activity-7171170319980871680-in91?utm_source=share&utm_medium=member_desktop) &#124; [code](https://numbersman77.github.io/kasparrufibach/code/futility_fp/20240306_futility_fp.html) &#124;|\n|2024-03-01: **Why and what a non-statistician should know about causal inference** &#124; [link](https://www.linkedin.com/posts/kasparrufibach_biostatistics-causalinference-activity-7169401987397066752-aA2P?utm_source=share&utm_medium=member_desktop) &#124;|\n|2023-11-10: **Implementation of statistical innovation in a pharmaceutical company** &#124; [link](https://www.linkedin.com/posts/kasparrufibach_innovation-biostatistics-estimand-activity-7128840875215855616-WxVA?utm_source=share&utm_medium=member_desktop) &#124;|\n|2023-10-13: **Futility analyses -- they are a strategic tool in drug development and not at all futile!** &#124; [link](https://www.linkedin.com/posts/kasparrufibach_biostatistics-clinicaltrial-interimanalysis-activity-7118537293337907200-i7ui?utm_source=share&utm_medium=member_desktop) &#124;|\n|2023-10-12: **Crossover in oncology trials - presentation at FDA / Lungevity statistical forum** &#124; [link](https://www.linkedin.com/posts/kasparrufibach_biostatistics-clinicaltrials-oncology-activity-7118305540534874112-MiCU?utm_source=share&utm_medium=member_desktop) &#124;|\n|2023-08-09: **Minimal detectable difference in a trial with time-to-event primary endpoint** &#124; [link](https://www.linkedin.com/posts/kasparrufibach_here-is-a-question-for-anyone-working-on-activity-7094488116748529664-9TYr?utm_source=share&utm_medium=member_desktop) &#124; [code](code/mdd/20230809_mdd.html) &#124;|\n|2023-08-05: **Discussion of JSM session \"Recent advances in Bayesian power and probability of success\", providing punch lines of my talk on quantitative decision-making** &#124; [link](https://www.linkedin.com/posts/kasparrufibach_supporting-quantitative-decision-making-about-activity-7093541725926760448-Dnqn?utm_source=share&utm_medium=member_desktop) &#124;|\n|2023-07-12: **Statistical Methodology Leaders in Drug Development** &#124; [link](https://www.linkedin.com/posts/kasparrufibach_biostatistics-statistics-drugdevelopment-activity-7084613881087578113-teIX?utm_source=share&utm_medium=member_desktop) &#124;|\n|2023-07-06: **Summary of talk at BBS next generation event** &#124; [link](https://www.linkedin.com/posts/kasparrufibach_pharmaindustry-work-experience-activity-7082629933637722112-FxSC?utm_source=share&utm_medium=member_desktop) &#124;|\n|2023-07-05: **Effective statistician podcast on driving statistical innovation** &#124; [link](https://www.linkedin.com/posts/kasparrufibach_drugdevelopment-innovation-biostatistics-activity-7082025955627552769-iWml?utm_source=share&utm_medium=member_desktop) &#124;|\n|2023-06-06: **Why can't we simply get rid of RCTs?** &#124; [link](https://www.linkedin.com/posts/kasparrufibach_clinicaltrials-estimands-randomization-activity-7071772566452854785-yxZs?utm_source=share&utm_medium=member_desktop) &#124;|\n|2023-06-05: **Why do we randomize in RCTs?** &#124; [link](https://www.linkedin.com/posts/kasparrufibach_clinicaltrials-randomization-rwd-activity-7071398951765065728-blQn?utm_source=share&utm_medium=member_desktop) &#124;|\n|2023-04-02: **Why do we do interim analyses in clinical trials?** &#124; [link](https://www.linkedin.com/posts/kasparrufibach_clinicaltrials-drugdevelopment-like-activity-7048390244101943296-xr7j?utm_source=share&utm_medium=member_desktop) &#124;|\n|2023-03-29: **Quantification of follow-up** &#124; [link](https://www.linkedin.com/posts/kasparrufibach_oncology-estimand-working-group-activity-7046725113534132226-3uW5?utm_source=share&utm_medium=member_desktop) &#124;|\n|2023-03-07: **How can the estimands addendum framework be “married” with competing risks?** &#124; [link](https://www.linkedin.com/posts/kasparrufibach_biostatistics-estimand-drugdevelopment-activity-7038765477778620416-oNH9?utm_source=share&utm_medium=member_desktop) &#124;|\n|2023-02-02: **Trial design using multistate modelling for PFS and OS** &#124; [link](https://www.linkedin.com/posts/kasparrufibach_oncology-multistate-survivalanalysis-activity-7024352913275678720-f1p1?utm_source=share&utm_medium=member_desktop) &#124;|\n|2023-01-04: **Estimation of AE risk in RCTs** &#124; [link](https://www.linkedin.com/posts/kasparrufibach_biostatistics-timetoevent-safety-activity-6997583241654206464-Bh1y?utm_source=share&utm_medium=member_desktop) &#124;|\n|2022-12-02: **Are regulators on board with estimands?** &#124; [link](https://www.linkedin.com/pulse/regulators-board-estimands-kaspar-rufibach/) &#124;                                      |\n|2022-05-01: **Thoughts on my 10th year anniversary at Roche** &#124; [link](https://www.linkedin.com/posts/kasparrufibach_drugdevelopment-science-biostatistics-activity-6926819927689461760-tjzF?utm_source=share&utm_medium=member_desktop) &#124;|\n|2022-02-09: **Academia - Industry collaboration award of Ulm University for Roche's long-term collaboration with Jan Beyersmann** &#124; [link](https://www.linkedin.com/posts/kasparrufibach_dies-academicus-2022-activity-6899251846717026304-Bo0N?utm_source=share&utm_medium=member_desktop) &#124;|\n:::\n:::\n\n::: {.cell}\n\n:::\n\n# Posts on twitter {-} \n\n::: {.cell}\n::: {.cell-output-display}\n|                                                                                                                                                                       |\n|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n|2022-06-13: **Follow-up quantification for time-to-event endpoint: Asking the right questions and make numbers meaningful** &#124; [link](https://twitter.com/numbersman77/status/1536264526181679106) &#124;|\n|2022-06-11: **Clinical and Statistical Perspectives on the ICH E9(R1) Estimand Framework Implementation: paper jointly by industry - FDA authors.** &#124; [link](https://twitter.com/numbersman77/status/1535610871174549506) &#124;|\n|2021-05-10: **Event prediction in RCTs w/ T2E endpoint** &#124; [link](https://twitter.com/numbersman77/status/1391851038727102465) &#124;                             |\n|2021-03-10: **Stop the abuse: plea for more principled approach to analysis of AEs.** &#124; [link](https://twitter.com/numbersman77/status/1369704328605351936) &#124;|\n|2020-11-13: **How can we use futility interim analyses (FIA) to mitigate risks in accelerated drug development?** &#124; [link](https://twitter.com/numbersman77/status/1327299501586075650) &#124;|\n|2020-11-11: **Why do we run group-sequential trials in drug development?** &#124; [link](https://twitter.com/numbersman77/status/1326548973411135490) &#124;           |\n|2020-11-09: **Why does pharma industry announce top-line trial results in press releases before publishing a scientific paper?** &#124; [link](https://twitter.com/numbersman77/status/1325828499085602818) &#124;|\n:::\n:::\n\n\n:::",
    "supporting": [],
    "filters": [
      "rmarkdown/pagebreak.lua"
    ],
    "includes": {},
    "engineDependencies": {},
    "preserve": {},
    "postProcess": true
  }
}